2. Signaling Pathways
  3. Epigenetics
  4. Histone Methyltransferase
  5. Histone Methyltransferase Isoform
  6. Histone Methyltransferase Inhibitor

Histone Methyltransferase Inhibitor

Histone Methyltransferase Inhibitors (197):

Cat. No. Product Name Effect Purity
  • HY-126300
    SGC6870
    		Inhibitor
    SGC6870 is a potent, selective and cytoactive allosteric inhibitor of PRMT6 with IC50 of 77 nM.
  • HY-155818
    NSD2-IN-4
    		Inhibitor
    NSD2-IN-4 is a potent and selective NSD2-SET inhibitor. NSD2-IN-4 has the potential for NSD2-related diseases.
  • HY-139823A
    PRMT5-IN-11
    		Inhibitor
    PRMT5-IN-11 is a promising structure-dependent inhibition of the protein methyltransferase PRMT5:MEP50 complex in the (sub)micromolar range.
  • HY-172732
    PRMT5-IN-50
    		Inhibitor
    PRMT5-IN-50 is an orally active and selective inhibitor of PRMT5. PRMT5-IN-50 has good metabolic stability and low clearance rate in human liver microsomes. PRMT5-IN-50 inhibits SDMA/HCT116-MTAPdel and SDMA/HCT116-MTAPwt with IC50s value of 1.0, 536 nM for arginine symmetric methylation, 19, 1620 nM for anti-proliferation, respectively. PRMT5-IN-50 inhibits tumor growth in mice.
  • HY-138886
    RL5a
    		Inhibitor
    RL5a (compund C23) is a SETD8 inhibitor.
  • HY-115758
    PRMT1-IN-1
    		Inhibitor
    PRMT1-IN-1 is a PRMT1 inhibitor.
  • HY-139823
    PRMT5-IN-10
    		Inhibitor
    PRMT5-IN-10 has promising structure-dependent inhibition of the protein methyltransferase PRMT5:MEP50 complex.
  • HY-142093
    NSD3-IN-1
    		Inhibitor
    NSD3-IN-1 (compound B1) is an inhibitor of histone methyltransferase NSD3 with an IC50 value of 28.58 μM.
  • HY-145444
    EPZ028862
    		Inhibitor
    EPZ028862 is a selective SMYD3 inhibitor for cancer research.
  • HY-104009
    GSK2807
    		Inhibitor
    GSK2807 is a potent and selective SAM-competitive inhibitor of SMYD3, exhibiting a Ki value of 14 nM, and it may be useful for cancer treatment by preventing the methylation of MEKK2.
  • HY-161869
    LSD1-IN-32
    		Inhibitor
    LSD1-IN-32 (compound 11e) is a potent LSD1 inhibitor with an IC50 value of 0.99 µM. LSD1-IN-32 inhibits RANKL-induced osteoclastogenesis, bone resorption and F-actin belt formation. LSD1-IN-32 has the potential for the research of osteoporosis.
  • HY-172368
    PROTAC CARM1/IKZF3 degrader-1
    		Inhibitor
    PROTAC CARM1/IKZF3 degrader-1 (Compound 074) inhibits CARM1, reduces the methylation level of its substrate BAF155. PROTAC CARM1/IKZF3 degrader-1 is the PROTAC degrader for IKZF 1/3 through a CRBN-dependent pathway. PROTAC CARM1/IKZF3 degrader-1 inhibits the expression of MYC protein, thereby inhibiting the proliferation of a variety of multiple myeloma cells. PROTAC CARM1/IKZF3 degrader-1 induces apoptosis in cell H929. PROTAC CARM1/IKZF3 degrader-1 overcomes immunomodulatory drugs (IMiD, such as pomalidomide) resistance. PROTAC CARM1/IKZF3 degrader-1 can be used in cancer and immunology research. (Pink: ligand for target protein CARM1/IKZF3 ligand 1 (HY-172369); Active form of target protein ligand: EZM 2302 (HY-111109); Black: linker (HY-21999); Blue: ligand for E3 ligase Cereblon Thalidomide 4-fluoride (HY-41547))
  • HY-172197
    MRK-990
    		Inhibitor
    MRK-990 is the inhibitor for PRMT that inhibits PRMT5 and PRMT9 with IC50 of 30 nM and 10 nM.
  • HY-111589
    EPZ-4777
    		Inhibitor
    EPZ-4777 is a selective DOT1L inhibitor which inhibits H3K79 methylation in cancer cells, blocks the expression of leukemogenic genes, and selectively kills cells that contain the translocation. EPZ-4777 can be used for cancer research.
  • HY-142094
    NSD3-IN-2
    		Inhibitor
    NSD3-IN-2 is a potent NSD3 inhibitor with an IC50 value of 17.97 μM. NSD3-IN-2 inhibits the growth and proliferation of non-small cell lung cancer cell lines H460, H1299 and H1650 with anti-cancer activity.
  • HY-44062
    G9a-IN-1
    		Inhibitor 98.12%
    G9a-IN-1 (Compound 113) is a G9a protein inhibitor. G9A/EHMT2 is a nuclear histone lysine methyltransferase that catalyzes histone H3 lysine 9 dimethylation (H3K9me2), which is a reversible modification generally associated with transcriptional gene silencing. G9a-IN-1 can be used for the research of autoimmune disorders or cancer.
  • HY-160865
    PRMT5-IN-35
    		Inhibitor 99.63%
    PRMT5-IN-35 (Compound 87) is a potent, selective and orally active PRMT5 inhibitor with an IC50 value of 1 nM . PRMT5-IN-35 can be used in cancer research.
  • HY-158157
    ZL-28-6
    		Inhibitor
    ZL-28-6 is a type I PRMT inhibitor (IC50: 18 nM). ZL-28-6 effectively targets CARM1 (a member of PRMT) within cells and can be used for cancer research.
  • HY-B1322R
    Amodiaquine (dihydrochloride dihydrate) (Standard)
    		Inhibitor
    Amodiaquine (dihydrochloride dihydrate) (Standard) is the analytical standard of Amodiaquine (dihydrochloride dihydrate). This product is intended for research and analytical applications. Amodiaquine dihydrochloride dihydrate (Amodiaquin dihydrochloride dihydrate), a 4-aminoquinoline class of antimalarial agent, is a potent and orally active histamine N-methyltransferase inhibitor. Amodiaquine dihydrochloride dihydrate is also a Nurr1 agonist and specifically binds to Nurr1-LBD (ligand binding domain) with an EC50 of ~20 μM. Anti-inflammatory effect.
  • HY-118715
    Setin-1
    		Inhibitor
    Setin-1 is one of the most potent inhibitors of Set7, acting by inhibiting KMTase G9a.